AbbVie seeks OK for new hepatitis C drug

AbbVie Inc. has applied for U.S. approval of a new treatment for hepatitis C.

The North Chicago-based drugmaker said Tuesday testing of the new drug involved more than 2,300 patients in 25 countries. AbbVie expects to seek approval in the European Union in May.

“This (New Drug Application) submission is a significant advancement for AbbVie’s HCV development program,” said Dr. Scott Brun, the company’s vice president of pharmaceutical development. “We believe our all-oral, interferon-free regimen holds the potential to be a promising new therapy for patients living with this chronic infection.”

The company says about 3.2 million people in the U.S. live with the hepatitis C virus.

$ABBV’s NDA in the US for its investigational #HCV regimen represents a milestone for the company http://t.co/w2sirqqHt1
— AbbVie (@abbvie) April 22, 2014

AbbVie to move 2,000 employees off North Chicago campus

Drugmaker AbbVie to set up plant in Singapore

AbbVie earnings hurt by generic drugs

Next Up In News

Netflix looks to curb password sharing, considers ads

Aiming to predict COVID, future pandemics better, CDC opens infectious diseases forecasting center

Joliet farmers wrangle cows thrown from semitrailer after crash on Interstate 80

1 killed, 3 wounded in shootings Tuesday in Chicago

Obama relatives sue Milwaukee school alleging racial bias

Unmasked transit: Pritzker ends mask mandates in public transportation, airports